StockData
Halozyme Therapeutics, Inc. logo

Halozyme Therapeutics, Inc. (HALO) stock

HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.80−0.17 (-0.18%)

Close on Nov 18, 2026Market cap $10.87BP/E 28.3Yield –

Halozyme Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Halozyme Therapeutics's price to book ratio was 80.8× on Nov 11, 2026, against 16.7× a year earlier. Over the last 5 years it ranged from 13.3× to 167.8×, with a median of 27.8×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202680.8×+65.1
2025Dec 31, 202515.7×+2.3
2024Dec 31, 202413.4×−6.2
2023Dec 29, 202319.6×−59.7
2022Dec 30, 202279.3×+59.2
2021Dec 31, 202120.1×−38.3
2020Dec 31, 202058.4×+47.8
2019Dec 31, 201910.6×+1.8
2018Dec 31, 20188.8×−31.0
2017Dec 29, 201739.8×−72.8
2016Oct 31, 2016112.6×+42.9
2015Dec 31, 201569.7×+39.3
2014Dec 31, 201430.3×−88.1
2013Oct 31, 2013118.4×+103.7
2012Dec 31, 201214.8×−21.7
2011Dec 30, 201136.4×–

More Halozyme Therapeutics figures

See a number that looks wrong?